Acadia Pharmaceuticals (ACAD) Financials: History & Chart

Acadia Pharmaceuticals Inc.(ACAD)

Biotechnology · San Diego, CA

$19.79-0.32 (-1.60%)

Delayed quote: Oct 6, 2026, 2:50 PM EDT

About Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

San Diego, CA

797 employees

www.acadia.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Catherine E. Owen Adams

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.14B	307.96M	268.06M	283.99M	278.63M	264.57M	244.32M	259.60M	250.40M
Cost of Goods Sold	100.98M	28.32M	24.79M	26.23M	21.65M	20.73M	20.39M	21.80M	18.86M
Gross Profit	1.04B	279.64M	243.27M	257.76M	256.99M	243.83M	223.93M	237.80M	231.54M
Gross Profit Margin	91.1%	90.8%	90.8%	90.8%	92.2%	92.2%	91.7%	91.6%	92.5%
Total Operating Expenses	951.30M	241.81M	247.89M	240.37M	221.23M	211.46M	204.63M	84.30M	199.90M
Research & Development	331.01M	81.56M	76.87M	84.76M	87.83M	77.95M	78.27M	100.73M	66.61M
Selling, General & Administrative	620.29M	160.25M	171.02M	155.62M	133.40M	133.51M	126.37M	130.08M	133.29M
Operating Income (EBIT)	86.37M	37.84M	-4.62M	17.39M	35.76M	32.37M	19.29M	153.50M	31.64M
Operating Margin	7.6%	12.3%	-1.7%	6.1%	12.8%	12.2%	7.9%	59.1%	12.6%
Income Before Tax (EBT)	121.37M	46.47M	3.98M	26.32M	44.59M	40.21M	27.78M	161.09M	38.81M
Interest Income	32.62M	7.99M	8.05M	8.33M	8.25M	7.24M	7.90M	7.01M	6.59M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	35.00M	8.64M	8.60M	8.93M	8.84M	7.84M	8.49M	7.58M	7.16M
Net Income	380.48M	31.50M	3.64M	273.57M	71.78M	26.67M	18.99M	143.74M	32.77M
Income Tax Expense	-259.12M	14.97M	344K	-247.25M	-27.18M	13.54M	8.79M	17.34M	6.04M
Net Profit Margin	33.4%	10.2%	1.4%	96.3%	25.8%	10.1%	7.8%	55.4%	13.1%
EBITDA	98.39M	40.99M	-1.62M	20.32M	38.71M	35.31M	22.24M	158.72M	34.21M
EBITDA Margin	8.6%	13.3%	-0.6%	7.2%	13.9%	13.3%	9.1%	61.1%	13.7%
Depreciation & Amortization	12.02M	3.16M	2.99M	2.92M	2.95M	2.94M	2.95M	5.21M	2.57M
EPS Basic	2.25	0.18	0.02	1.62	0.43	0.16	0.11	0.86	0.20
EPS Diluted	2.22	0.18	0.02	1.60	0.42	0.16	0.11	0.86	0.20
Weighted Average Basic Shares	171.60M	171.60M	170.52M	169.34M	168.84M	167.83M	166.81M	166.36M	165.97M
Weighted Average Diluted Shares	172.85M	172.85M	172.71M	171.36M	170.65M	168.68M	167.67M	166.36M	166.18M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	1.07B	957.80M	726.44M	517.24M	484.14M	441.75M	339.08M	223.81M
Cost of Goods Sold	89.00M	81.84M	45.73M	10.17M	19.14M	20.55M	19.60M	18.33M
Gross Profit	982.51M	875.96M	680.71M	507.07M	465.00M	421.20M	319.48M	205.48M
Gross Profit Margin	91.7%	91.5%	93.7%	98.0%	96.0%	95.3%	94.2%	91.8%
Total Operating Expenses	877.70M	645.16M	754.09M	730.66M	635.44M	707.79M	566.02M	452.92M
Research & Development	328.80M	303.25M	351.62M	361.57M	239.41M	319.13M	240.38M	187.16M
Selling, General & Administrative	548.89M	488.43M	402.47M	369.09M	396.03M	388.66M	325.64M	265.76M
Operating Income (EBIT)	104.81M	230.79M	-73.38M	-223.60M	-170.44M	-286.59M	-246.54M	-247.44M
Operating Margin	9.8%	24.1%	-10.1%	-43.2%	-35.2%	-64.9%	-72.7%	-110.6%
Income Before Tax (EBT)	138.90M	258.07M	-51.04M	-213.44M	-167.52M	-280.97M	-234.38M	-243.94M
Interest Income	31.72M	25.46M	17.23M	6.61M	591K	6.61M	11.16M	5.35M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	34.09M	27.28M	22.34M	10.15M	2.92M	5.61M	12.16M	3.51M
Net Income	391.00M	226.45M	-61.29M	-215.97M	-167.87M	-281.58M	-235.26M	-245.19M
Income Tax Expense	-252.10M	31.62M	10.25M	2.53M	351K	611K	876K	1.26M
Net Profit Margin	36.5%	23.6%	-8.4%	-41.8%	-34.7%	-63.7%	-69.4%	-109.6%
EBITDA	116.57M	246.68M	-67.83M	-221.57M	-167.09M	-283.65M	-243.78M	-244.44M
EBITDA Margin	10.9%	25.8%	-9.3%	-42.8%	-34.5%	-64.2%	-71.9%	-109.2%
Depreciation & Amortization	11.76M	15.88M	5.55M	2.03M	3.34M	2.93M	2.77M	3.00M
EPS Basic	2.32	1.37	-0.37	-1.34	-1.05	-1.79	-1.60	-1.94
EPS Diluted	2.29	1.36	-0.37	-1.34	-1.05	-1.79	-1.60	-1.94
Weighted Average Basic Shares	169.34M	165.72M	163.82M	161.68M	160.49M	157.33M	147.20M	126.58M
Weighted Average Diluted Shares	171.36M	166.36M	163.82M	161.68M	160.49M	157.33M	147.20M	126.58M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.